Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy
A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Proof-of-Concept Study of GIC-1001 for the Management of Visceral Pain in Subjects Undergoing Sedation-Free, Full Colonoscopy
Status: Enrolling
Updated:  12/19/2013
Avail Clinical Research
mi
from
DeLand, FL
A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy
A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Proof-of-Concept Study of GIC-1001 for the Management of Visceral Pain in Subjects Undergoing Sedation-Free, Full Colonoscopy
Status: Enrolling
Updated: 12/19/2013
Avail Clinical Research
mi
from
DeLand, FL
Click here to add this to my saved trials
A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy
A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Proof-of-Concept Study of GIC-1001 for the Management of Visceral Pain in Subjects Undergoing Sedation-Free, Full Colonoscopy
Status: Enrolling
Updated:  12/19/2013
The Center for GI Disorders
mi
from
Hollywood, FL
A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy
A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Proof-of-Concept Study of GIC-1001 for the Management of Visceral Pain in Subjects Undergoing Sedation-Free, Full Colonoscopy
Status: Enrolling
Updated: 12/19/2013
The Center for GI Disorders
mi
from
Hollywood, FL
Click here to add this to my saved trials
A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy
A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Proof-of-Concept Study of GIC-1001 for the Management of Visceral Pain in Subjects Undergoing Sedation-Free, Full Colonoscopy
Status: Enrolling
Updated:  12/19/2013
Mid-Atlantic Medical Research Centers
mi
from
Hollywood, MD
A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy
A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Proof-of-Concept Study of GIC-1001 for the Management of Visceral Pain in Subjects Undergoing Sedation-Free, Full Colonoscopy
Status: Enrolling
Updated: 12/19/2013
Mid-Atlantic Medical Research Centers
mi
from
Hollywood, MD
Click here to add this to my saved trials
A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy
A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Proof-of-Concept Study of GIC-1001 for the Management of Visceral Pain in Subjects Undergoing Sedation-Free, Full Colonoscopy
Status: Enrolling
Updated:  12/19/2013
Mayo Clinic Rochester
mi
from
Rochester, MN
A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy
A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Proof-of-Concept Study of GIC-1001 for the Management of Visceral Pain in Subjects Undergoing Sedation-Free, Full Colonoscopy
Status: Enrolling
Updated: 12/19/2013
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy
A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Proof-of-Concept Study of GIC-1001 for the Management of Visceral Pain in Subjects Undergoing Sedation-Free, Full Colonoscopy
Status: Enrolling
Updated:  12/19/2013
PharmaTrials
mi
from
Hillsborough, NJ
A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy
A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Proof-of-Concept Study of GIC-1001 for the Management of Visceral Pain in Subjects Undergoing Sedation-Free, Full Colonoscopy
Status: Enrolling
Updated: 12/19/2013
PharmaTrials
mi
from
Hillsborough, NJ
Click here to add this to my saved trials
A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy
A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Proof-of-Concept Study of GIC-1001 for the Management of Visceral Pain in Subjects Undergoing Sedation-Free, Full Colonoscopy
Status: Enrolling
Updated:  12/19/2013
Montefiore Medical Center
mi
from
Bronx, NY
A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy
A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Proof-of-Concept Study of GIC-1001 for the Management of Visceral Pain in Subjects Undergoing Sedation-Free, Full Colonoscopy
Status: Enrolling
Updated: 12/19/2013
Montefiore Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy
A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Proof-of-Concept Study of GIC-1001 for the Management of Visceral Pain in Subjects Undergoing Sedation-Free, Full Colonoscopy
Status: Enrolling
Updated:  12/19/2013
Gastroenterology Associates of Orangeburg, PA
mi
from
Orangeburg, SC
A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy
A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Proof-of-Concept Study of GIC-1001 for the Management of Visceral Pain in Subjects Undergoing Sedation-Free, Full Colonoscopy
Status: Enrolling
Updated: 12/19/2013
Gastroenterology Associates of Orangeburg, PA
mi
from
Orangeburg, SC
Click here to add this to my saved trials
Postoperative Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic T2-T3N0 Prostate Cancer
A Phase I/II Trial of Post-Prostatectomy Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic T2-T3NO Prostate Cancer
Status: Enrolling
Updated:  12/30/2013
University of Kansas Medical Center
mi
from
Kansas City, KA
Postoperative Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic T2-T3N0 Prostate Cancer
A Phase I/II Trial of Post-Prostatectomy Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic T2-T3NO Prostate Cancer
Status: Enrolling
Updated: 12/30/2013
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Targeted Atomic Nano-Generators (Actinium-225-Labeled Humanized Anti-CD33 Monoclonal Antibody HuM195) in Patients With Advanced Myeloid Malignancies
Phase I Trial of Targeted Atomic Nano-Generators (Actinium-225-Labeled Humanized Anti-CD33 Monoclonal Antibody HuM195) in Patients With Advanced Myeloid Malignancies
Status: Enrolling
Updated:  1/3/2014
Memorial Sloan-Kettering Cancer Center
mi
from
New York, NY
Targeted Atomic Nano-Generators (Actinium-225-Labeled Humanized Anti-CD33 Monoclonal Antibody HuM195) in Patients With Advanced Myeloid Malignancies
Phase I Trial of Targeted Atomic Nano-Generators (Actinium-225-Labeled Humanized Anti-CD33 Monoclonal Antibody HuM195) in Patients With Advanced Myeloid Malignancies
Status: Enrolling
Updated: 1/3/2014
Memorial Sloan-Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
A Study of DS-2248, in Subjects With Advanced Solid Tumors
A Phase 1, Open-Label, Multiple-Ascending-Dose Study of DS-2248, an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  1/6/2014
Clinical Research Facility
mi
from
Duarte, CA
A Study of DS-2248, in Subjects With Advanced Solid Tumors
A Phase 1, Open-Label, Multiple-Ascending-Dose Study of DS-2248, an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 1/6/2014
Clinical Research Facility
mi
from
Duarte, CA
Click here to add this to my saved trials
A Study of DS-2248, in Subjects With Advanced Solid Tumors
A Phase 1, Open-Label, Multiple-Ascending-Dose Study of DS-2248, an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  1/6/2014
Clinical Research Facility
mi
from
Loma Linda, CA
A Study of DS-2248, in Subjects With Advanced Solid Tumors
A Phase 1, Open-Label, Multiple-Ascending-Dose Study of DS-2248, an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 1/6/2014
Clinical Research Facility
mi
from
Loma Linda, CA
Click here to add this to my saved trials
A Study of DS-2248, in Subjects With Advanced Solid Tumors
A Phase 1, Open-Label, Multiple-Ascending-Dose Study of DS-2248, an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  1/6/2014
Clinical Research Facility
mi
from
Orange, CA
A Study of DS-2248, in Subjects With Advanced Solid Tumors
A Phase 1, Open-Label, Multiple-Ascending-Dose Study of DS-2248, an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 1/6/2014
Clinical Research Facility
mi
from
Orange, CA
Click here to add this to my saved trials
A Study of DS-2248, in Subjects With Advanced Solid Tumors
A Phase 1, Open-Label, Multiple-Ascending-Dose Study of DS-2248, an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  1/6/2014
Clinical Research Facility
mi
from
Orlando, FL
A Study of DS-2248, in Subjects With Advanced Solid Tumors
A Phase 1, Open-Label, Multiple-Ascending-Dose Study of DS-2248, an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 1/6/2014
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
A Study of DS-2248, in Subjects With Advanced Solid Tumors
A Phase 1, Open-Label, Multiple-Ascending-Dose Study of DS-2248, an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  1/6/2014
Clinical Research Facility
mi
from
Indianapolis, IN
A Study of DS-2248, in Subjects With Advanced Solid Tumors
A Phase 1, Open-Label, Multiple-Ascending-Dose Study of DS-2248, an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 1/6/2014
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Study of DS-2248, in Subjects With Advanced Solid Tumors
A Phase 1, Open-Label, Multiple-Ascending-Dose Study of DS-2248, an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  1/6/2014
Clinical Research Facility
mi
from
Detroit, MI
A Study of DS-2248, in Subjects With Advanced Solid Tumors
A Phase 1, Open-Label, Multiple-Ascending-Dose Study of DS-2248, an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 1/6/2014
Clinical Research Facility
mi
from
Detroit, MI
Click here to add this to my saved trials
A Study of DS-2248, in Subjects With Advanced Solid Tumors
A Phase 1, Open-Label, Multiple-Ascending-Dose Study of DS-2248, an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  1/6/2014
Clinical Research Facility
mi
from
Portland, OR
A Study of DS-2248, in Subjects With Advanced Solid Tumors
A Phase 1, Open-Label, Multiple-Ascending-Dose Study of DS-2248, an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 1/6/2014
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
A Study of DS-2248, in Subjects With Advanced Solid Tumors
A Phase 1, Open-Label, Multiple-Ascending-Dose Study of DS-2248, an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  1/6/2014
Clinical Research Facility
mi
from
San Antonio, TX
A Study of DS-2248, in Subjects With Advanced Solid Tumors
A Phase 1, Open-Label, Multiple-Ascending-Dose Study of DS-2248, an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 1/6/2014
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Study of DS-2248, in Subjects With Advanced Solid Tumors
A Phase 1, Open-Label, Multiple-Ascending-Dose Study of DS-2248, an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  1/6/2014
Clinical Research Facility
mi
from
Seattle, WA
A Study of DS-2248, in Subjects With Advanced Solid Tumors
A Phase 1, Open-Label, Multiple-Ascending-Dose Study of DS-2248, an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 1/6/2014
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
C11 AMT Positron Emission Tomography (PET) Imaging in Patients With Metastatic Invasive Breast Cancer
NCI 8701: A Pilot Study Utilizing C11 Alpha Methyl Tryptophan (AMT) PET Functional Imaging in Patients With Metastatic Invasive Breast Cancer Treated With 1 Methyl D Tryptophan Plus the Ad p53 DC Vaccine
Status: Enrolling
Updated:  1/7/2014
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
C11 AMT Positron Emission Tomography (PET) Imaging in Patients With Metastatic Invasive Breast Cancer
NCI 8701: A Pilot Study Utilizing C11 Alpha Methyl Tryptophan (AMT) PET Functional Imaging in Patients With Metastatic Invasive Breast Cancer Treated With 1 Methyl D Tryptophan Plus the Ad p53 DC Vaccine
Status: Enrolling
Updated: 1/7/2014
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
Radial Reload Open LAR Case Series
Evaluating the Radial Reload Stapler With Tri-Staple TM Technology During Open Low Anterior Resection for Rectal Cancer: A Prospective Multicenter Case Series
Status: Enrolling
Updated:  1/7/2014
University of South Florida
mi
from
Tampa, FL
Radial Reload Open LAR Case Series
Evaluating the Radial Reload Stapler With Tri-Staple TM Technology During Open Low Anterior Resection for Rectal Cancer: A Prospective Multicenter Case Series
Status: Enrolling
Updated: 1/7/2014
University of South Florida
mi
from
Tampa, FL
Click here to add this to my saved trials
Radial Reload Open LAR Case Series
Evaluating the Radial Reload Stapler With Tri-Staple TM Technology During Open Low Anterior Resection for Rectal Cancer: A Prospective Multicenter Case Series
Status: Enrolling
Updated:  1/7/2014
Duke University
mi
from
Durham, NC
Radial Reload Open LAR Case Series
Evaluating the Radial Reload Stapler With Tri-Staple TM Technology During Open Low Anterior Resection for Rectal Cancer: A Prospective Multicenter Case Series
Status: Enrolling
Updated: 1/7/2014
Duke University
mi
from
Durham, NC
Click here to add this to my saved trials
Radial Reload Open LAR Case Series
Evaluating the Radial Reload Stapler With Tri-Staple TM Technology During Open Low Anterior Resection for Rectal Cancer: A Prospective Multicenter Case Series
Status: Enrolling
Updated:  1/7/2014
Providence Medical Center
mi
from
Spokane, WA
Radial Reload Open LAR Case Series
Evaluating the Radial Reload Stapler With Tri-Staple TM Technology During Open Low Anterior Resection for Rectal Cancer: A Prospective Multicenter Case Series
Status: Enrolling
Updated: 1/7/2014
Providence Medical Center
mi
from
Spokane, WA
Click here to add this to my saved trials
Vibro-Acoustography Imaging in Diagnosing Breast Masses in Women With a Breast Mass or Breast Cancer
Identification and Differentiation of Breast Masses by Vibro-Acoustography
Status: Enrolling
Updated:  1/8/2014
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Vibro-Acoustography Imaging in Diagnosing Breast Masses in Women With a Breast Mass or Breast Cancer
Identification and Differentiation of Breast Masses by Vibro-Acoustography
Status: Enrolling
Updated: 1/8/2014
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Click here to add this to my saved trials
Cryospray Ablation of Surgical Resection Specimens To Determine Safety And Histological Effect In The Lung
A Study Of Cryospray Ablationtm Using Surgical Resection Specimens To Determine Safety And Histological Effect In The Lung
Status: Enrolling
Updated:  1/8/2014
Franklin Square Hospital Center
mi
from
Baltimore, MD
Cryospray Ablation of Surgical Resection Specimens To Determine Safety And Histological Effect In The Lung
A Study Of Cryospray Ablationtm Using Surgical Resection Specimens To Determine Safety And Histological Effect In The Lung
Status: Enrolling
Updated: 1/8/2014
Franklin Square Hospital Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer
A Phase I/II Study of MGCD265 in Combination With Erlotinib or Docetaxel in Subjects With Advanced Malignancies and in Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  1/9/2014
Barbara Ann Karmanos Cancer Center
mi
from
Detroit, MI
A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer
A Phase I/II Study of MGCD265 in Combination With Erlotinib or Docetaxel in Subjects With Advanced Malignancies and in Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 1/9/2014
Barbara Ann Karmanos Cancer Center
mi
from
Detroit, MI
Click here to add this to my saved trials
A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer
A Phase I/II Study of MGCD265 in Combination With Erlotinib or Docetaxel in Subjects With Advanced Malignancies and in Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  1/9/2014
Duke Univ Med Ctr
mi
from
Durham, NC
A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer
A Phase I/II Study of MGCD265 in Combination With Erlotinib or Docetaxel in Subjects With Advanced Malignancies and in Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 1/9/2014
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer
A Phase I/II Study of MGCD265 in Combination With Erlotinib or Docetaxel in Subjects With Advanced Malignancies and in Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  1/9/2014
University of Pennsylvania:Abramson Cancer Center
mi
from
Philadelphia, PA
A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer
A Phase I/II Study of MGCD265 in Combination With Erlotinib or Docetaxel in Subjects With Advanced Malignancies and in Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 1/9/2014
University of Pennsylvania:Abramson Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer
A Phase I/II Study of MGCD265 in Combination With Erlotinib or Docetaxel in Subjects With Advanced Malignancies and in Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  1/9/2014
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer
A Phase I/II Study of MGCD265 in Combination With Erlotinib or Docetaxel in Subjects With Advanced Malignancies and in Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 1/9/2014
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer
A Phase I/II Study of MGCD265 in Combination With Erlotinib or Docetaxel in Subjects With Advanced Malignancies and in Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  1/9/2014
South Texas Accelerated Research Therapeutics
mi
from
San Antonio, TX
A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer
A Phase I/II Study of MGCD265 in Combination With Erlotinib or Docetaxel in Subjects With Advanced Malignancies and in Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 1/9/2014
South Texas Accelerated Research Therapeutics
mi
from
San Antonio, TX
Click here to add this to my saved trials
Circulating Cell-free DNA as a Predictive Biomarker for Hepatocelluar Carcinoma.
Detected the Valuable Characteristic Changes Both in Circulating Cell-free DNA and Primary Tumor in the Patients With Hepatocelluar Carcinoma.
Status: Enrolling
Updated:  1/12/2014
Stanford Genome Technology Center
mi
from
Stanford, CA
Circulating Cell-free DNA as a Predictive Biomarker for Hepatocelluar Carcinoma.
Detected the Valuable Characteristic Changes Both in Circulating Cell-free DNA and Primary Tumor in the Patients With Hepatocelluar Carcinoma.
Status: Enrolling
Updated: 1/12/2014
Stanford Genome Technology Center
mi
from
Stanford, CA
Click here to add this to my saved trials
[18]F-Fluciclatide for Kidney Cancer Imaging Studies and Treatment
A Pilot, Open-label, Proof-of-Concept Study of the Use of [18F] Fluciclatide PET/CT Imaging in the Evaluation of Anti-AngiogenicTherapy in Renal Cancers
Status: Enrolling
Updated:  1/16/2014
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
[18]F-Fluciclatide for Kidney Cancer Imaging Studies and Treatment
A Pilot, Open-label, Proof-of-Concept Study of the Use of [18F] Fluciclatide PET/CT Imaging in the Evaluation of Anti-AngiogenicTherapy in Renal Cancers
Status: Enrolling
Updated: 1/16/2014
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
Carboplatin Plus Docetaxel (Taxotere) in Anaplastic Prostate Cancer
Phase II Study of Carboplatin Plus Docetaxel (Taxotere) in Patients With Anaplastic Prostate Carcinoma
Status: Enrolling
Updated:  1/16/2014
University of California at San Francisco
mi
from
San Francisco, CA
Carboplatin Plus Docetaxel (Taxotere) in Anaplastic Prostate Cancer
Phase II Study of Carboplatin Plus Docetaxel (Taxotere) in Patients With Anaplastic Prostate Carcinoma
Status: Enrolling
Updated: 1/16/2014
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Carboplatin Plus Docetaxel (Taxotere) in Anaplastic Prostate Cancer
Phase II Study of Carboplatin Plus Docetaxel (Taxotere) in Patients With Anaplastic Prostate Carcinoma
Status: Enrolling
Updated:  1/16/2014
UT MD Anderson Cancer Center
mi
from
Houston, TX
Carboplatin Plus Docetaxel (Taxotere) in Anaplastic Prostate Cancer
Phase II Study of Carboplatin Plus Docetaxel (Taxotere) in Patients With Anaplastic Prostate Carcinoma
Status: Enrolling
Updated: 1/16/2014
UT MD Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 in Subjects With Advanced Solid Tumors
Phase 1 Study of the Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 in Subjects With Advanced Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy is Available
Status: Enrolling
Updated:  1/17/2014
Clinical Research Facility
mi
from
Peoria, IL
A Study of Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 in Subjects With Advanced Solid Tumors
Phase 1 Study of the Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 in Subjects With Advanced Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy is Available
Status: Enrolling
Updated: 1/17/2014
Clinical Research Facility
mi
from
Peoria, IL
Click here to add this to my saved trials
A Study of Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 in Subjects With Advanced Solid Tumors
Phase 1 Study of the Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 in Subjects With Advanced Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy is Available
Status: Enrolling
Updated:  1/17/2014
Clinical Research Facility
mi
from
Indianapolis, IN
A Study of Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 in Subjects With Advanced Solid Tumors
Phase 1 Study of the Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 in Subjects With Advanced Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy is Available
Status: Enrolling
Updated: 1/17/2014
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Study of Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 in Subjects With Advanced Solid Tumors
Phase 1 Study of the Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 in Subjects With Advanced Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy is Available
Status: Enrolling
Updated:  1/17/2014
Clinical Research Facility
mi
from
Boston, MA
A Study of Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 in Subjects With Advanced Solid Tumors
Phase 1 Study of the Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 in Subjects With Advanced Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy is Available
Status: Enrolling
Updated: 1/17/2014
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 in Subjects With Advanced Solid Tumors
Phase 1 Study of the Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 in Subjects With Advanced Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy is Available
Status: Enrolling
Updated:  1/17/2014
Clinical Research Facility
mi
from
New York, NY
A Study of Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 in Subjects With Advanced Solid Tumors
Phase 1 Study of the Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 in Subjects With Advanced Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy is Available
Status: Enrolling
Updated: 1/17/2014
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Compare Preperitoneal Analgesia to Epidural Analgesia for Pain Control After Colon and Rectal Surgery
Prospective Randomized Clinical Trial to Compare Continuous Preperitoneal Analgesia to Continuous Epidural Analgesia for Pain Control After Colon and Rectal Surgery
Status: Enrolling
Updated:  1/20/2014
Saint Joseph Mercy Hospital
mi
from
Ann Arbor, MI
Compare Preperitoneal Analgesia to Epidural Analgesia for Pain Control After Colon and Rectal Surgery
Prospective Randomized Clinical Trial to Compare Continuous Preperitoneal Analgesia to Continuous Epidural Analgesia for Pain Control After Colon and Rectal Surgery
Status: Enrolling
Updated: 1/20/2014
Saint Joseph Mercy Hospital
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Powered Echelon Device in VATS Surgery
A Prospective, Multi-Center Evaluation of a Powered Surgical Stapler in Video-Assisted Thoracoscopic Lung Resection Procedures
Status: Enrolling
Updated:  1/20/2014
Dignity Health, St. Joseph's Hospital & Medical Center
mi
from
Phoenix, AZ
Powered Echelon Device in VATS Surgery
A Prospective, Multi-Center Evaluation of a Powered Surgical Stapler in Video-Assisted Thoracoscopic Lung Resection Procedures
Status: Enrolling
Updated: 1/20/2014
Dignity Health, St. Joseph's Hospital & Medical Center
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Powered Echelon Device in VATS Surgery
A Prospective, Multi-Center Evaluation of a Powered Surgical Stapler in Video-Assisted Thoracoscopic Lung Resection Procedures
Status: Enrolling
Updated:  1/20/2014
Massachusetts General Hospital
mi
from
Boston, MA
Powered Echelon Device in VATS Surgery
A Prospective, Multi-Center Evaluation of a Powered Surgical Stapler in Video-Assisted Thoracoscopic Lung Resection Procedures
Status: Enrolling
Updated: 1/20/2014
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Powered Echelon Device in VATS Surgery
A Prospective, Multi-Center Evaluation of a Powered Surgical Stapler in Video-Assisted Thoracoscopic Lung Resection Procedures
Status: Enrolling
Updated:  1/20/2014
Washington University School of Medicine
mi
from
Saint Louis, MO
Powered Echelon Device in VATS Surgery
A Prospective, Multi-Center Evaluation of a Powered Surgical Stapler in Video-Assisted Thoracoscopic Lung Resection Procedures
Status: Enrolling
Updated: 1/20/2014
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Powered Echelon Device in VATS Surgery
A Prospective, Multi-Center Evaluation of a Powered Surgical Stapler in Video-Assisted Thoracoscopic Lung Resection Procedures
Status: Enrolling
Updated:  1/20/2014
Vanderbilt University
mi
from
Nashville, TN
Powered Echelon Device in VATS Surgery
A Prospective, Multi-Center Evaluation of a Powered Surgical Stapler in Video-Assisted Thoracoscopic Lung Resection Procedures
Status: Enrolling
Updated: 1/20/2014
Vanderbilt University
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study of Gemzar, Taxotere, and Xeloda for Adjuvant Pancreatic Cancer
A Phase II Study of Gemzar, Taxotere, and Xeloda (GTX) for Adjuvant Pancreatic Cancer
Status: Enrolling
Updated:  1/22/2014
Columbia University Medical Center
mi
from
New York, NY
A Study of Gemzar, Taxotere, and Xeloda for Adjuvant Pancreatic Cancer
A Phase II Study of Gemzar, Taxotere, and Xeloda (GTX) for Adjuvant Pancreatic Cancer
Status: Enrolling
Updated: 1/22/2014
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer
A Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in Patients With KRAS Mutant NSCLC
Status: Enrolling
Updated:  1/22/2014
University of Colorado Denver
mi
from
Aurora, CO
Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer
A Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in Patients With KRAS Mutant NSCLC
Status: Enrolling
Updated: 1/22/2014
University of Colorado Denver
mi
from
Aurora, CO
Click here to add this to my saved trials
Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer
A Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in Patients With KRAS Mutant NSCLC
Status: Enrolling
Updated:  1/22/2014
Moffitt Cancer Center
mi
from
Tampa, FL
Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer
A Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in Patients With KRAS Mutant NSCLC
Status: Enrolling
Updated: 1/22/2014
Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer
A Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in Patients With KRAS Mutant NSCLC
Status: Enrolling
Updated:  1/22/2014
Dana-Farber Cancer Institute
mi
from
Boston, MA
Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer
A Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in Patients With KRAS Mutant NSCLC
Status: Enrolling
Updated: 1/22/2014
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer
A Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in Patients With KRAS Mutant NSCLC
Status: Enrolling
Updated:  1/22/2014
Massachusetts General Hospital
mi
from
Boston, MA
Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer
A Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in Patients With KRAS Mutant NSCLC
Status: Enrolling
Updated: 1/22/2014
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer
A Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in Patients With KRAS Mutant NSCLC
Status: Enrolling
Updated:  1/22/2014
Memorial Sloan-Kettering Cancer Center
mi
from
New York, NY
Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer
A Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in Patients With KRAS Mutant NSCLC
Status: Enrolling
Updated: 1/22/2014
Memorial Sloan-Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Phase 1 Study of CEP-37250/KHK2804 in Subjects With Advanced Solid Tumors
Two-Part, Open-Label, Multi-Center Phase 1 Study of Monoclonal Antibody CEP-37250/KHK2804 in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  1/22/2014
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Phase 1 Study of CEP-37250/KHK2804 in Subjects With Advanced Solid Tumors
Two-Part, Open-Label, Multi-Center Phase 1 Study of Monoclonal Antibody CEP-37250/KHK2804 in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 1/22/2014
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Phase 1 Study of CEP-37250/KHK2804 in Subjects With Advanced Solid Tumors
Two-Part, Open-Label, Multi-Center Phase 1 Study of Monoclonal Antibody CEP-37250/KHK2804 in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  1/22/2014
Emroy University
mi
from
Atlanta, GA
Phase 1 Study of CEP-37250/KHK2804 in Subjects With Advanced Solid Tumors
Two-Part, Open-Label, Multi-Center Phase 1 Study of Monoclonal Antibody CEP-37250/KHK2804 in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 1/22/2014
Emroy University
mi
from
Atlanta, GA
Click here to add this to my saved trials